Employees: 33
Size SanBio (4592.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $386M, the 1197th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥808 on 18 Nov 2026.
Performance Over six months the shares fell 55.4%, against -20.3% for the median peer and -1.4% for the Japan market (cap-weighted) — 3rd lowest of 19 in its peer set.
Next results Next results expected around 15 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -¥31.5M | -¥8.05M | -¥9.37M | -¥14.5M | -¥24.6M |
| EBITDA | -¥3.79B | -¥3.79B | -¥3.51B | -¥4.53B | -¥7.87B |
| Net income | -¥3.64B | -¥3.84B | -¥2.88B | -¥2.64B | -¥5.56B |
| Free cash flow | n/a | -¥3.84B | -¥3.62B | -¥4.79B | -¥7.46B |
| Capital expenditure | n/a | ¥32.8M | ¥4.89M | ¥55.0M | ¥8.00M |
| Total debt | ¥1.13B | ¥1.24B | ¥397M | ¥665M | ¥933M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4592.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.7% | -13.1% | 10th highest of 20 |
| 6-month return | -55.4% | -20.3% | 3rd lowest of 19 |
| Distance from 52-week high | -71.4% | -39.2% | 4th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SanBio 4592.T | Japan | $386M | -55% | n/a | n/a | n/a | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $386M | -2% | -21% | 8% | 3.7× | 20.9% | +28.2% |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $387M | n/a | +222% | 54% | 32.0× | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $384M | -54% | -23% | -3% | 6.2× | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $387M | +28% | -12% | -140% | 71.6× | n/a | n/a |
| Avalo Therapeutics AVTX | United States | $387M | -59% | -69% | -161,961% | n/a | n/a | n/a |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $388M | -17% | +9% | 19% | 2.2× | -5.5% | +12.2% |
| Heartseed 219A.T | Japan | $392M | +53% | +197% | 9% | 21.9× | 46.5% | +73.2% |
| JCR Pharmaceuticals 4552.T | Japan | $379M | -5% | +3% | -14% | 2.9× | n/a | n/a |
| Opus Genetics IRD | United States | $379M | -22% | -46% | -778% | 41.2× | n/a | n/a |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $374M | -51% | -8% | -23% | 4.4× | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $398M | -13% | -3% | 2% | 3.4× | 14.9% | +13.7% |
| Puma Biotechnology PBYI | United States | $373M | +3% | +9% | 11% | 1.2× | 0.1% | +0.3% |
| ARS Pharmaceuticals SPRY | United States | $371M | -53% | -14% | -162% | 2.9× | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $371M | -1% | -1% | -13% | 4.9× | 22.2% | -15.7% |
| MapLight Therapeutics MPLT | United States | $370M | -76% | n/a | n/a | n/a | n/a | n/a |
| 6467 6467.TW | Taiwan | $368M | n/a | n/a | -2,618% | 1,407.9× | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $368M | -33% | +7% | -2% | 7.2× | n/a | n/a |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $405M | -24% | +91% | -65% | 7.9× | n/a | n/a |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $406M | -18% | -16% | 2% | 1.9× | 9.2% | +6.7% |
| Lumosa Therapeutics 6535.TWO | Taiwan | $406M | -37% | -25% | -803% | 399.1× | n/a | n/a |